Entering text into the input field will update the search result below

FDA OKs expanded use for Glaxo's Nucala; shares up 1%

Dec. 12, 2017 10:43 AM ETGSK plc (GSK) StockGSKBy: Douglas W. House, SA News Editor
  • The FDA approves the use of GlaxoSmithKline's (GSK +0.6%) Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis, a rare autoimmune disorder that causes blood vessel inflammation.
  • Nucala was first approved in the U.S. in 2015 for eosinophilic asthma.

Recommended For You

More Trending News

About GSK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
GSK--
GSK plc